Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center, Open-label, Randomized, Two-period, Two-way Crossover Study to Investigate the Bioequivalence of a Single-dose of 12 mg IVERMECTIN Administered as Orally Disintegrating Mini Tablets (CHILD-IVITAB) Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets (STROMECTOL) in Healthy Adults Under Fasting Conditions

NCT05477810 is registered in ClinicalTrials.gov with University Children's Hospital Basel as lead sponsor.

NCT NCT05477810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05477810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center, Open-label, Randomized, Two-period, Two-way Crossover Study to Investigate the Bioequivalence of a Single-dose of 12 mg IVERMECTIN Administered as Orally Disintegrating Mini Tablets (CHILD-IVITAB) Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets (STROMECTOL) in Healthy Adults Under Fasting Conditions
Lead sponsor
University Children's Hospital Basel
Phase
Phase 1
Overall status
Completed
Start date
September 13, 2022
Completion date
December 15, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence